The historical development of immunoendocrine concepts of psychiatric disorders and their therapy

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 28841-28869

  Steinberg, Holger ^a   Kirkby, Kenneth C ^b   Himmerich, Hubertus ^a,c  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF TASMANIA   (Australia)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cytokines; Depression; History of psychiatry; Hormones; Immune system; Schizophrenia

Indexed keywords

CD4 ANTIGEN; GONADORELIN; INTERLEUKIN 2 RECEPTOR ALPHA; HORMONE;

BLOOD ANALYSIS; BODY TEMPERATURE MEASUREMENT; CASTRATION; CONVULSIVE THERAPY; DEPRESSION; ELECTROCONVULSIVE THERAPY; ENDOCRINE DISEASE; HOMOSEXUALITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOLOGY; MENTAL DISEASE; NONHUMAN; OVARIECTOMY; PSYCHIATRY; RADIOIMMUNOASSAY; REVIEW; SCHIZOPHRENIA; ANIMAL; COMPLICATION; DEPRESSIVE DISORDER; HISTORY; IMMUNOPATHOLOGY; MENTAL DISORDERS;

ANIMALS; DEPRESSIVE DISORDER; ENDOCRINE SYSTEM DISEASES; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HORMONES; HUMANS; IMMUNE SYSTEM DISEASES; MENTAL DISORDERS; SCHIZOPHRENIA;

EID: 84949434153     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226136     Document Type: Review

References (159)

1. Müller, N.; Schwarz, M.J. Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders. Expert Rev. Neurother. 2006, 6, 1017–1038. [CrossRef] [PubMed]
2. Himmerich, H.; Steinberg, H. Hormonelle Krankheits-und Therapiekonzepte in der Psychiatrie. Fortschr. Neurol. Psychiatr. 2011, 79, 384–394. [CrossRef] [PubMed]
3. Kleine, B.; Rossmanith, W.G. Hormone und Hormonsystem. Lehrbuch der Endokrinologie, 2nd ed.; Springer: Berlin, Germany, 2010.
4. Nadler, M. Tierische Arbeitskraft im Neolithikum?—Belege von Ochsen im frühen Jungneolithikum von Marktbergel, Mittelfranken. In Schleife, Schlitten, Rad undWagen. Zur Frage früher Transportmittel nördlich der Alpen; Köninger, J., Mainberger, M., Schlichtherle, H., Eds.; Janus: Freiburg, Germany, 2002; pp. 109–110.
5. Walkowitz, J.E. Logistik im Neolithikum und Chalcolithikum. In Varia Neolithica IV; Beier, H.J., Ed.; Beier & Beran: Langenweißbach, Germany, 2006; pp. 123–151.
6. King James Bible (KJV) quoted from The King James Bible Online—Authorized Version. Available online: http://www.kingjamesbibleonline.org/Matthew-Chapter-19 (accessed on 14 August 2015).
7. Steinberg, H., Paul Julius Möbius (1853–1907). J. Neurol. 2005, 252, 624–625. [CrossRef] [PubMed]
8. Steinberg, H. Als ob ich zu einer steinernen Wand spräche. In Der Nervenarzt Paul Julius Möbius-Eine Werkbiografie; Hans Huber Verlag: Bern, Switzerland, 2005.
9. Steinberg, H. Zum 150. Geburtstag von Paul Julius Möbius (1853–1907). Anmerkungen zum Titelbild. Nervenarzt 2004, 75, 97–100. [CrossRef] [PubMed]
10. Möbius, P.J. Über die Wirkungen der Kastration; Marhold: Halle, Germany, 1903.
11. Splett, T.; Steinberg, H. Die Therapie der Hysterie im 19. Jahrhundert—Wie stand die deutsche Psychiatrie zur Kastration? Fortschr. Neurol. Psychiatr. 2003, 71, 45–52. [CrossRef] [PubMed]
12. Steinberg, H. Diesmal hat der Referent Kraepelins neue Eintheilung mit Stolz und Befriedigung begrüsst, denn es ist seine eigene. Die ätiologische Klassifikation der Nerven-und psychischen Krankheiten von Paul Julius Möbius. Fortschr. Neurol. Psychiatr. 2006, 74, 149–156. [CrossRef] [PubMed]
13. Huonker, T. Anstaltseinweisungen, Kindswegnahmen, Eheverbote, Sterilisationen, Kastrationen-Fürsorge, Zwangsmassnahmen, “Eugenik” und Psychiatrie in Zürich zwischen 1890 und 1970; Sozialdepartement: Zürich, Switzerland, 2002.
14. Druhm, K.W. A welcome return to Draconia: California Penal Law 645, the castration of sex offenders and the constitution. Albany Law Rev. 1997, 61, 285–343.
15. Scott, C.L.; Holmberg, T. Castration of sex offenders: Prisoners’ rights versus public safety. J. Am. Acad. Psychiatr. Law 2003, 31, 502–509.
16. Lombroso, C. Der Verbrecher in Anthropologischer, Ärztlicher und Juristischer Beziehung; Richter: Hamburg, Germany, 1887.
17. Gadebusch-Bondio, M. Die Rezeption der Kriminalanthropologischen Theorien von Cesare Lombroso in Deutschland von 1880–1914; Matthiesen: Husum, Germany, 1995.
18. Jensch, N. Untersuchungen an Entmannten Sittlichkeitsverbrechern. Sammlung psychiatrischer und neurologischer Einzeldarstellungen; Thieme: Leipzig, Germany, 1944.
19. Wolfert, R.; Steinberg, H. Der Homosexuelle als “störende Persönlichkeit” Nikolaus Jensch und seine psychiatrisch-genetischen Studien. Fortschr. Neurol. Psychiatr. 2009, 77, 444–450. [CrossRef] [PubMed]
20. Lemke, R. Neue Auffassungen zur Pathogenese, Klinik und strafrechtlichen Stellung der männlichen und weiblichen Homosexualität. Med. Klin. 1940, 36, 1355–1357.
21. Moll, A. Behandlung der Homosexualität: Biochemisch oder Psychisch?; Marcus &Weber: Bonn, Germany, 1921.
22. Eckart, W.U. Das Krankheits-und Therapiekonzept der hippokratischen Medizin. In Geschichte der Medizin; Eckart, W.U., Ed.; Springer: Heidelberg, Germany, 2009; pp. 33–34.
23. Lanczik, M.; Bergant, A.; Klier, C. Are severe psychiatric disorders in childbed of endogenous or organic nature? German contributions to the biological, nosological and psychopathological research in postpartum psychosis in the 18th and 19th century. Arch. Womens Ment. Health 2006, 9, 293–299. [CrossRef] [PubMed]
24. Schott, H. Medizingeschichte(n) Psychiatrie. Wahn (Schwangerschaftspsychose). Dtsch. Arztebl. 2004, 101, A-2397/B-2017/C-1945.
25. Wagner-Jauregg, J. Myxödem und Kretinismus; Deuticke: Leipzig, Germany, 1912.
26. Kocher, T. Über Kropfexstirpation und ihre Folgen. Arch. Klin. Chir. 1883, 29, 254–337.
27. Strümpell, A. Lehrbuch der Speciellen Pathologie und Therapie der Inneren Krankheiten. Für Studierende und Ärzte. Vol II: Krankheiten des Nervensystems; Vogel: Leipzig, Germany, 1884.
28. Von Basedow K.A. Exophthalmus durch Hypertrophie des Zellgewebes in der Augenhöhle. Wschrft. Ges. Heilkd. 1840, 6, 197–204.
29. Möbius, P.J. Ueber dasWesen der Basedow’schen Krankheit. Cbl. Nervenheilkd. Psychiatr. 1887, 10, 225–229.
30. Möbius, P.J. Vom Verhältnisse der Poliomyelencephalitis zur Basedow’schen Krankheit von Dr. E. Jendrassik. Schmidts Jb. Ges. Med. 1886, 210, 237–238.
31. Hertz, S.; Roberts, A. Application of radioactive iodine in therapy of Graves’ disease. J. Clin. Investig. 1942, 21, 624.
32. Astwood, E.B. Treatment of hyperthyroidism with thiourea and thiouracil. JAMA 1943, 122, 78–81. [CrossRef]
33. Addison, T. On the constitutional and local effects of disease of the suprarenal capsule. In A Collection of the Published Writings of the Late Thomas Addison MD; Daldy, T.M., Wilks, S., Eds.; New Sydenham Society: London, UK, 1868; pp. 211–239.
34. Cushing, H. The Pituitary Body and Its Disorders; Lippincott: Philadelphia, PA, USA; London, UK, 1912; p. 217.
35. Cushing, H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull. Johns Hopkins Hosp. 1932, 50, 137–195. [CrossRef]
36. Cushing, H. Psychiatric disturbances associated with disorders of the ductless glands. Am. J. Insanity 1913, 69, 965–990.
37. Aldrich, T.B. A preliminary report on the active principle of the suprarenal gland. Am. J. Physiol. 1901, 5, 457–461.
38. Takamine, J. Adrenalin; the active principle of the suprarenal gland. Am. J. Pharm. 1901, 73, 523–531.
39. Bayliss, W.M.; Starling, E.H. The mechanism of pancreatic secretion. J. Physiol. 1902, 28, 325–353. [CrossRef] [PubMed]
40. Kendall, E.C.; Osterberg, A.E. The chemical identification of thyroxin. J. Biol. Chem. 1919, 40, 265–334.
41. Banting, F.G. Early work on Insulin. Science 1937, 85, 594–596. [CrossRef] [PubMed]
42. Piosik, R. Adolf Butenandt und sein Wirken an der Technischen Hochschule Danzig. Chemkon 2003, 10, 135–138. [CrossRef]
43. Zhang, Y.; Proenca, R.; Maffei, M.; Barone, M.; Leopold, L.; Friedman, J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372, 425–432. [CrossRef] [PubMed]
44. Kojima, M.; Hosoda, H.; Date, Y.; Nakazato, M.; Matsuo, H.; Kangawa, K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402, 656–660. [CrossRef] [PubMed]
45. Bernhardt, D. Introduction and Overview. In Hormones and Human Behaviour; Donovan, B.T., Ed.; Cambridge University Press: New York, NY, USA; Cambridge, UK, 1985; pp. 1–16.
46. Bleuler, M. Untersuchungen aus dem Grenzgebiet zwischen Psychopathologie und Endokrinologie. Arch. Psychiatr. Nervenkrankht. 1948, 180, 271–528.
47. Bleuler, M. Endokrinologische Psychiatrie; Thieme: Stuttgart, Germany, 1954.
48. Schüssler, P.; Yassouridis, A.; Uhr, M.; Kluge, M.; Bleninger, P.; Holsboer, F.; Steiger, A. Sleep and active renin levels—Interaction with age, gender, growth hormone and cortisol. Neuropsychobiology 2010, 61, 113–121. [CrossRef] [PubMed]
49. Bleuler, M. Endokrinologische Psychiatrie. In Psychiatrie der Gegenwart, 2nd ed.; Kisker, K.P., Meyer, J.E., Müller, M., Eds.; Springer: Berlin, Germany, 1979; pp. 257–342.
50. Himmerich, H.; Veselinović, T.; Habel, U. Affektive Störungen bei Frauen. Die Stimmung im Spiegel der weiblichen Lebensphasen. Inf. Neurol. Psychiatr. 2009, 11, 42–26.
51. Ripping, L.H. Die Geistesstörungen der Schwangeren, Wöchnerinnen und Säugenden; Enke: Stuttgart, Germany, 1877.
52. Schmidt, M. Beiträge zur Kenntnis der Puerperalpsychosen. Arch. Psychiatr. Nervenkrankht. 1881, 11, 75–95. [CrossRef]
53. Boyce, P.; Barriball, E. Puerperal psychosis. Arch. Womens Ment. Health 2010, 13, 45–47. [CrossRef] [PubMed]
54. Mayer, L. Die Beziehungen der krankhaften Zustände in den Sexual-Organen des Weibes zu Geistesstörungen; Hirschwald: Berlin, Germany, 1869.
55. Von Reitzenstein, F. Iwan Bloch †. Sexualreform 1922, 11, 113–126.
56. Sakel, M. Neue Behandlungsmethode der Schizophrenie; Perles: Vienna, Austria, 1935.
57. Walther, T. Die “Insulin-Koma-Behandlung”. Erfindung und Einführung des Ersten Modernen Psychiatrischen Schockverfahrens; Lehmann Antipsychiatrieverlag: Berlin, Germany, 2004.
58. Dengler, K. Erfahrungen bei Behandlung von 16 männlichen Schizophrenen mit Choriongonadotropin/ Depottestosteron. Arch. Psychiatr. Nervenkrankht. Z. Ges. Neurol. Psychiatr. 1961, 202, 481–503. [CrossRef]
59. Bujanow, W. Hormones in the treatment of psychoses. Br. Med. J. 1972, 4, 298. [CrossRef] [PubMed]
60. Linde, O.K. Historischer Abriss: Geschichte der Psychopharmaka. In Neuro-Psychopharmaka; Riederer, P., Laux, G., Pöldinger, W., Eds.; Springer: Vienna, Austria, 1992; Volume 1, pp. 41–66.
61. Benkert, O.; Hippius, H. Kompendium der Psychiatrischen Pharmakotherapie, 7th ed.; Springer: Heidelberg, Germany, 2009.
62. Yalow, R.S.; Berson, S.A. Assay of plasma insulin in human subjects by immunological methods. Nature 1959, 184, 1648–1649. [CrossRef] [PubMed]
63. Berghoff, E. Zur Beeinflussung chronischer Krankheiten durch interkurrentes Fieber. Klin. Wochenschr. 1931, 10, 2138–2140. [CrossRef]
64. Ilberg, J. Über Fiebertherapie bei Nervenkrankheiten im Altertum. Allg. Z. Psychiatr. 1929, 91, 353–354.
65. Stahl, G.E. Theoria Medica Vera; Orphanotrophei: Halle, Germany, 1707.
66. Steinberg, H. Kraepelin in Leipzig. Eine Begegnung von Psychiatrie und Psychologie; Psychiatrie-Verlag: Bonn, Germany, 2001.
67. Kraepelin, E. Ueber den Einfluss acuter Krankheiten auf die Entstehung von Geisteskrankheiten. Arch. Psychiatr. Nervenkrankht. 1881, 11, 137–183. [CrossRef]
68. Steinberg, H.; Himmerich, H. Kraepelin’s habilitation and his thesis: A pioneer work for modern systematic reviews, psychoimmunological research and categories of psychiatric diseases. World J. Biol. Psychiatry 2013, 14, 248–257. [CrossRef] [PubMed]
69. Carswell, E.A.; Old, L.J.; Kassel, R.L.; Green, S.; Fiore, N.; Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 1975, 72, 3666–3670. [CrossRef] [PubMed]
70. Bruce, L.C.; Peebles, A.M.S. Quantitative and qualitative leukocyte counts in the various forms of mental disease. J. Ment. Sci. 1904, 50, 409–412.
71. Bruce, L.C.; Peebles, A.M.S. Clinical and experimental observations on catatonia. J. Ment. Sci. 1903, 49, 614–628.
72. Bruce, L.C. On the experimental use of antiserums in acute insanity. J. Ment. Sci. 1904, 50, 259–262. [CrossRef]
73. Dameshek, W. White blood cells in dementia praecox and dementia paralytica. Arch. Neurol. Psychiatry 1930, 24, 855.
74. Whitrow, M. Wagner-Jauregg and fever therapy. Med. Hist. 1990, 34, 294–310. [CrossRef] [PubMed]
75. Whitrow, M. Julius Wagner-Jauregg (1857–1940); Facultas: Vienna, Austria, 2001.
76. Brown, E.M. WhyWagner-Jauregg won the Nobel-Prize for discovering malaria therapy for general paresis of the insane. Hist. Psychiatry 2000, 11, 371–382. [CrossRef]
77. Wagner-Jauregg, J. Über die Einwirkung der Malaria auf die progressive Paralyse. Psychiatr. Neurol. Wochenschr. 1918, 20, 132–134.
78. Himmerich, H.; Kirkby, K.C.; Steinberg, H. From Julius Wagner-Jauregg to biomarkers and immunological therapies. World J. Biol. Psychiatry 2010, 11, 154–155. [CrossRef] [PubMed]
79. Wagner-Jauregg, J. Fieberbehandlung bei Psychosen. Wien. Klin. Wochenschr. 1926, 76, 79–82.
80. Wagner-Jauregg, J. Infektions-und Fiebertherapie; Weidmann: Vienna, Austria, 1936.
81. Wagner-Jauregg, J. Derzeitige Behandlung der progressiven Paralyse. Wien. Klin. Wochenschr. 1939, 52, 1075–1078.
82. Noll, R. Kraepelin’s lost biological psychiatry? Autointoxication, organotherapy and surgery for dementia praecox. Hist. Psychiatry 2007, 18, 301–320. [CrossRef] [PubMed]
83. Noll, R. Historical review: Autointoxication and focal infection theories of dementia praecox. World J. Biol. Psychiatry 2004, 5, 66–72. [CrossRef] [PubMed]
84. Lehmann-Facius, H. Über die Liquordiagnose der Schizophrenien. Klin. Wochenschr. 1937, 16, 1646–1648. [CrossRef]
85. Lehmann-Facius, H. Serologisch-analytische Versuche mit Liquoren und Seren von Schizophrenen. Allg. Z. Psychiatr. 1939, 110, 232–243.
86. Roeder, F. Über die serologische Diagnostik der Schizophrenie aus dem Liquor nach der Methode von Lehmann-Facius. Z. Ges. Neurol. Psychiatr. 1939, 165, 462–467.
87. Göhde, W.; Dittrich, W. Impulse fluorometry of single cells in suspension. Z. Naturforsch. B 1969, 24, 360–361.
88. Köhler, G.; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256, 495–497. [CrossRef] [PubMed]
89. Gibbons, J.L.; McHugh, P.R. Plasma cortisol in depressive illness. J. Psychiatr. Res. 1962, 1, 162–171. [CrossRef]
90. Gibbons, J.L. Cortisol depression rate in depressive illness. Arch. Gen. Psychiatry 1964, 10, 572–575. [CrossRef] [PubMed]
91. Holsboer, F.; von Bardeleben, U.; Wiedemann, K.; Müller, O.A.; Stalla, G.K. Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression. Biol. Psychiatry 1987, 22, 228–234. [CrossRef]
92. Ising, M.; Künzel, H.E.; Binder, E.B.; Nickel, T.; Modell, S.; Holsboer, F. The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29, 1085–1093. [CrossRef] [PubMed]
93. Ströhle, A. Die Neuroendokrinologie von Stress und die Pathophysiologie und Therapie von Depression und Angst. Nervenarzt 2003, 74, 279–291. [CrossRef] [PubMed]
94. Gilpin, N.W.; Richardson, H.N.; Koob, G.F. Effects of CRF1-receptor and opioid-receptor antagonists on dependence-induced increases in alcohol drinking by alcohol-preferring (P) rats. Alcohol. Clin. Exp. Res. 2008, 32, 1535–1542. [CrossRef] [PubMed]
95. Jahn, H.; Döring, W.K.; Krampe, H.; Sieg, S.; Werner, C.; Poser, W.; Brunner, E.; Ehrenreich, H. Preserved vasopressin response to osmostimulation despite decreased basal vasopressin levels in longterm abstinent alcoholics. Alcohol. Clin. Exp. Res. 2004, 28, 1925–1930. [CrossRef] [PubMed]
96. Hundt, W.; Zimmermann, U.; Pöttig, M.; Spring, K.; Holsboer, F. The combined dexamethasone-suppression/CRH-stimulation test in alcoholics during and after acute withdrawal. Alcohol. Clin. Exp. Res. 2001, 25, 687–691. [CrossRef] [PubMed]
97. Zimmermann, U.; Spring, K.; Kunz-Ebrecht, S.R.; Uhr, M.; Wittchen, H.U.; Holsboer, F. Effect of ethanol on hypothalamic-pituitary-adrenal system response to psychosocial stress in sons of alcohol-dependent fathers. Neuropsychopharmacology 2004, 29, 1156–1165. [CrossRef] [PubMed]
98. Zimmermann, U.; Spring, K.; Wittchen, H.U.; Himmerich, H.; Landgraf, R.; Uhr, M.; Holsboer, F. Arginine vasopressin and adrenocorticotropin secretion in response to psychosocial stress is attenuated by ethanol in sons of alcohol-dependent fathers. J. Psychiatr. Res. 2004, 38, 385–393. [CrossRef] [PubMed]
99. Andrade, T.G.; Nakamuta, J.S.; Avanzi, V.; Graeff, F.G. Anxiolytic effect of estradiol in the median raphe nucleus mediated by 5-HT1A receptors. Behav. Brain Res. 2005, 163, 18–25. [CrossRef] [PubMed]
100. Estrada-Camarena, E.; Fernandez-Guasti, A.; Lopez-Rubalcava, C. Antidepressant-like effect of different estrogenic compounds in the forced swimming test. Neuropsychopharmacology 2003, 28, 830–838. [CrossRef] [PubMed]
101. Zarrouf, F.A.; Artz, S.; Griffith, J.; Sirbu, C.; Kommor, M. Testosterone and depression: Systematic review and meta-analysis. J. Psychiatr. Pract. 2009, 15, 289–305. [CrossRef] [PubMed]
102. Martel, M.M.; Klump, K.; Nigg, J.T.; Breedlove, S.M.; Sisk, C.L. Potential hormonal mechanisms of attention-deficit/hyperactivity disorder and major depressive disorder: A new perspective. Horm. Behav. 2009, 55, 465–479. [CrossRef] [PubMed]
103. Kanayama, G.; Hudson, J.I.; Pope, H.G., Jr. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: A looming public health concern? Drug Alcohol Depend. 2008, 98, 1–12. [CrossRef] [PubMed]
104. Malone, D.A., Jr.; Dimeff, R.J.; Lombardo, J.A.; Sample, R.H. Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users. Clin. J. Sport Med. 1995, 5, 25–31. [CrossRef] [PubMed]
105. Maayan, R.; Shaltiel, G.; Poyurovsky, M.; Ramadan, E.; Morad, O.; Nechmad, A.; Weizman, A.; Agam, G. Chronic lithium treatment affects rat brain and serum dehydroepiandrosterone (DHEA) and DHEAsulphate (DHEA-S) levels. Int. J. Neuropsychopharmacol. 2004, 7, 71–75. [CrossRef] [PubMed]
106. Ambar, G.; Chiavegatto, S. Anabolic-androgenic steroid treatment induces behavioral disinhibition and downregulation of serotonin receptor messenger RNA in the prefrontal cortex and amygdala of male mice. Genes Brain Behav. 2009, 8, 161–173. [CrossRef] [PubMed]
107. Pichlo, H.G. Transsexualismus–leistungsrechtliche und gutachterliche Kriterien für geschlechtsangleichende somatische Maßnahmen aus Sicht des MDK-Nordrhein. In Transsexualität und Intersexualität; Groß, D., Neuschäfer-Rube, C., Steinbetzer, J., Eds.; Medizinisch Wissenschaftliche Verlagsgesellschaft: Berlin, Germany, 2008; pp. 119–130.
108. Adli, M.; Bauer, M.; Rush, A.J. Algorithms and collaborative-care systems for depression: Are they effective and why? A Systematic Review. Biol. Psychiatry 2006, 59, 1029–1038. [CrossRef] [PubMed]
109. Prange, A.J. Novel uses of thyroid hormones in patients with affective disorders. Thyroid 1996, 6, 537–543. [CrossRef] [PubMed]
110. Aronson, R.; Offman, H.J.; Joffe, R.T.; Naylor, C.D. Triiodothyronine augmentation in the treatment of refractory depression. Arch. Gen. Psychiatry 1996, 53, 842–848. [CrossRef] [PubMed]
111. Altshuler, L.L.; Bauer, M.; Frye, M.A.; Gitlin, M.J.; Mintz, J.; Szuba, M.P.; Leight, K.L.; Whybrow, P.C. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am. J. Psychiatry 2001, 158, 1617–1622. [CrossRef] [PubMed]
112. Morton, G.J.; Cummings, D.E.; Baskin, D.G.; Barsh, G.S.; Schwartz, M.W. Central nervous system control of food intake and body weight. Nature 2006, 443, 289–295. [CrossRef] [PubMed]
113. Baumann, A.; Heitmann, S.; Bubendorff, V.; Himmerich, H. Laborwertveränderungen bei Anorexia nervosa. Praxis 2010, 99, 661–667. [CrossRef] [PubMed]
114. Himmerich, H.; Schönknecht, P.; Heitmann, S.; Sheldrick, A.J. Laboratory parameters and appetite regulators in patients with anorexia nervosa. J. Psychiatr. Pract. 2010, 16, 82–92. [CrossRef] [PubMed]
115. Nicolás, J.M.; Fernández-Solà, J.; Fatjó, F.; Casamitjana, R.; Bataller, R.; Sacanella, E.; Tobías, E.; Badía, E.; Estruch, R. Increased circulating leptin levels in chronic alcoholism. Alcohol. Clin. Exp. Res. 2001, 25, 83–88. [CrossRef] [PubMed]
116. Motivala, S.J.; Dang, J.; Obradovic, T.; Meadows, G.G.; Butch, A.W.; Irwin, M.R. Leptin and cellular and innate immunity in abstinent alcoholics and controls. Alcohol. Clin. Exp. Res. 2003, 27, 1819–1824. [CrossRef] [PubMed]
117. Fulda, S.; Linseisen, J.; Wolfram, G.; Himmerich, S.; Gedrich, K.; Pollmächer, T.; Himmerich, H. Leptin plasma levels in the general population: Influence of age, gender, bodyweight and medical history. Protein Pept. Lett. 2010, 17, 1436–1440. [CrossRef] [PubMed]
118. Kraus, T.; Reulbach, U.; Bayerlein, K.; Mugele, B.; Hillemacher, T.; Sperling, W.; Kornhuber, J.; Bleich, S. Leptin is associated with craving in females with alcoholism. Addict. Biol. 2004, 9, 213–219. [CrossRef] [PubMed]
119. Wurst, F.M.; Junghanns, K.; Thon, N. Alkoholabhängigkeit, craving und appetitregulierende hormone. Psychiatrie Psychother. 2009, 5, 106–109. [CrossRef]
120. Kraus, T.; Schanze, A.; Gröschl, M.; Salomé, N.; Heilig, M.; Moechars, D.; Datta, R.; Perrissoud, D.; Dickson, S.L.; Engel, J.A. Ghrelin levels are increased in alcoholism. Alcohol. Clin. Exp. Res. 2005, 29, 2154–2157. [CrossRef] [PubMed]
121. Jerlhag, E.; Egecioglu, E.; Landgren, S.; Salomé, N.; Heilig, M.; Moechars, D.; Datta, R.; Perrissoud, D.; Dickson, S.L.; Engel, J.A. Requirement of central ghrelin signaling for alcohol reward. Proc. Natl. Acad. Sci. USA 2009, 106, 11318–11323. [CrossRef] [PubMed]
122. Himmerich, H. Neuroimmunologie. In Handbuch der Psychopharmakologie; Holsboer, F., Gründer, G., Benkert, O., Eds.; Springer: Heidelberg, Germany, 2008; pp. 369–374.
123. Himmerich, H.; Sorge, S.; Kirkby, K.C.; Steinberg, H. Schizophrenic disorders. The development of immunological concepts and therapy in psychiatry. Nervenarzt 2012, 83, 7–15. [CrossRef] [PubMed]
124. Müller, N.; Schwarz, M.J. A psychoneuroimmunological perspective to Emil Kraepelin’s dichotomy: Schizophrenia and major depression as inflammatory CNS disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258, 97–106. [CrossRef] [PubMed]
125. Müller, N.; Schwarz, M.J. Immunologische Aspekte bei schizophrenen Störungen. Nervenarzt 2007, 78, 253–263. [CrossRef] [PubMed]
126. Stöber, G.; Ben-Shachar, D.; Cardon, M.; Falkai, P.; Fonteh, A.N.; Gawlik, M.; Glenthoj, B.Y.; Grunblatt, E.; Jablensky, A.; Kim, Y.K., et al. Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J. Biol. Psychiatry 2009, 10, 127–155. [CrossRef] [PubMed]
127. Müller, N.; Riedel, M.; Scheppach, C.; Brandstätter, B.; Sokullu, S.; Krampe, K.; Ulmschneider, M.; Engel, R.R.; Möller, H.J.; Schwarz, M.J. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry 2002, 159, 1029–1034. [CrossRef] [PubMed]
128. Wagner-Jauregg, J. Über die Einwirkung fieberhafter Erkrankungen auf Psychosen. Jb. Psychiatr. 1887, 7, 94–131.
129. Hänel, F.; Legatis, G. Therapeutic use of megaphen in pulmonary tuberculosis. Tuberkulosearzt 1954, 8, 636–638. [PubMed]
130. Pollmächer, T.; Hinze-Selch, D.; Mullington, J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 1996, 16, 403–409. [CrossRef] [PubMed]
131. Dalmau, J.; Gleichman, A.J.; Hughes, E.G.; Rossi, J.E.; Peng, X.; Lai, M.; Dessain, S.K.; Rosenfeld, M.R.; Balice-Gordon, R.; Lynch, D.R. Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. Lancet Neurol. 2008, 12, 1091–1098. [CrossRef]
132. Margari, F.; Petruzzelli, M.G.; Mianulli, R.; Campa, M.G.; Pastore, A.; Tampoia, M. Circulating anti-brain autoantibodies in schizophrenia and mood disorders. Psychiatry Res. 2015. [CrossRef] [PubMed]
133. Steiner, J.; Schiltz, K.; Bernstein, H.G.; Bogerts, B. Antineuronal antibodies against neurotransmitter receptors and synaptic proteins in schizophrenia: Current knowledge and clinical implications. CNS Drugs 2015, 29, 197–206. [CrossRef] [PubMed]
134. Steiner, J.; Walter, M.; Glanz, W.; Sarnyai, Z.; Bernstein, H.G.; Vielhaber, S.; Kästner, A.; Skalej, M.; Jordan, W.; Schiltz, K., et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: Specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013, 70, 271–278. [CrossRef] [PubMed]
135. Brown, A.S.; Begg, M.D.; Gravenstein, S.; Schaefer, C.A.; Wyatt, R.J.; Bresnahan, M.; Babulas, V.P.; Susser, E.S. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch. Gen. Psychiatry 2004, 61, 774–780. [CrossRef] [PubMed]
136. Smith, S.E.; Li, J.; Garbett, K.; Mirnics, K.; Patterson, P.H. Maternal immune activation alters fetal brain development through interleukin-6. J. Neurosci. 2007, 27, 10695–10702. [CrossRef] [PubMed]
137. Lipina, T.V.; Zai, C.; Hlousek, D.; Roder, J.C.; Wong, A.H. Maternal immune activation during gestation interacts with Disc1 point mutation to exacerbate schizophrenia-related behaviors in mice. J. Neurosci. 2013, 33, 7654–7666. [CrossRef] [PubMed]
138. Hsiao, E.Y.; McBride, S.W.; Hsien, S.; Sharon, G.; Hyde, E.R.; McCue, T.; Codelli, J.A.; Chow, J.; Reisman, S.E.; Petrosino, J.F., et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 2013, 155, 1451–1463. [CrossRef] [PubMed]
139. Bode, L.; Zimmermann, W.; Ferszt, R.; Steinbach, F.; Ludwig, H. Borna disease virus genome transcribed and expressed in psychiatric patients. Nat. Med. 1995, 1, 232–236. [CrossRef] [PubMed]
140. House, P.K.; Vyas, A.; Sapolsky, R. Predator cat odors activate sexual arousal pathways in brains of Toxoplasma gondii infected rats. PLoS ONE 2011, 6, e23277. [CrossRef] [PubMed]
141. Monroe, J.M.; Buckley, P.F.; Miller, B.J. Meta-analysis of anti-Toxoplasma gondii IgM antibodies in acute psychosis. Schizophr. Bull. 2015, 41, 989–998. [CrossRef] [PubMed]
142. Kim, Y.K.; Myint, A.M.; Verkerk, R.; Scharpe, S.; Steinbusch, H.; Leonard, B. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 2009, 59, 123–129. [CrossRef] [PubMed]
143. Dantzer, R.; O’Connor, J.C.; Freund, G.G.; Johnson, R.W.; Kelley, K.W. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9, 46–56. [CrossRef] [PubMed]
144. Reichenberg, A.; Yirmiya, R.; Schuld, A.; Kraus, T.; Haack, M.; Morag, A.; Pollmächer, T. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 2001, 58, 445–452. [CrossRef] [PubMed]
145. Himmerich, H.; Fulda, S.; Linseisen, J.; Seiler, H.; Wolfram, G.; Himmerich, S.; Gedrich, K.; Kloiber, S.; Lucae, S.; Ising, M., et al. Depression, comorbidities and the TNF-α system. Eur. Psychiatry 2008, 23, 421–429. [CrossRef] [PubMed]
146. Schmidt, F.M.; Lichtblau, N.; Minkwitz, J.; Chittka, T.; Thormann, J.; Kirkby, K.C.; Sander, C.; Mergl, R.; Faßhauer, M.; Stumvoll, M., et al. Cytokine levels in depressed and non-depressed subjects, and masking effects of obesity. J. Psychiatr. Res. 2014, 55, 29–34. [CrossRef] [PubMed]
147. Lichtblau, N.; Schmidt, F.M.; Schumann, R.; Kirkby, K.C.; Himmerich, H. Cytokines as biomarkers in depressive disorder: Current standing and prospects. Int. Rev. Psychiatry 2013, 25, 592–603. [CrossRef] [PubMed]
148. Tyring, S.; Gottlieb, A.; Papp, K.; Gordon, K.; Leonardi, C.; Wang, A.; Lalla, D.; Woolley, M.; Jahreis, A.; Zitnik, R., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367, 29–35. [CrossRef]
149. Krügel, U.; Fischer, J.; Radicke, S.; Sack, U.; Himmerich, H. Antidepressant effects of TNF-α blockade in an animal model of depression. J. Psychiatr. Res. 2013, 47, 611–616. [CrossRef] [PubMed]
150. Schmidt, F.M.; Kirkby, K.C.; Himmerich, H. The TNF-α inhibitor etanercept as monotherapy in treatment-resistant depression—Report of two cases. Psychiatr. Danub. 2014, 26, 288–290. [PubMed]
151. Müller, N.; Schwarz, M.J.; Dehning, S.; Douhe, A.; Cerovecki, A.; Goldstein-Müller, B.; Spellmann, I.; Hetzel, G.; Maino, K.; Kleindienst, N., et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 2006, 11, 680–684. [CrossRef] [PubMed]
152. Kenis, G.; Maes, M. Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol. 2002, 5, 401–412. [CrossRef] [PubMed]
153. Himmerich, H.; Fulda, S.; Sheldrick, A.J.; Plümäkers, B.; Rink, L. IFN-reduction by tricyclic antidepressants. Int. J. Psychiatry Med. 2010, 40, 413–424. [CrossRef] [PubMed]
154. Petersein, C.; Sack, U.; Mergl, R.; Schönherr, J.; Schmidt, F.M.; Lichtblau, N.; Kirkby, K.C.; Bauer, K.; Himmerich, H. Impact of lithium alone and in combination with antidepressants on cytokine production in vitro. J. Neural Transm. 2015, 122, 109–122. [CrossRef] [PubMed]
155. Munzer, A.; Sack, U.; Mergl, R.; Schönherr, J.; Petersein, C.; Bartsch, S.; Kirkby, K.C.; Bauer, K.; Himmerich, H. Impact of antidepressants on cytokine production of depressed patients in vitro. Toxins 2013, 5, 2227–2240. [CrossRef] [PubMed]
156. + regulatory T cells in health and disease. Clin. Exp. Pharmacol. Physiol. 2006, 33, 519–524. [CrossRef] [PubMed]
157. Himmerich, H.; Milenović, S.; Fulda, S.; Plümäkers, B.; Sheldrick, A.J.; Michel, T.M.; Kircher, T.; Rink, L. Regulatory T cells increased while IL-1β decreased during antidepressant therapy. J. Psychiatr. Res. 2010, 44, 1052–1057. [CrossRef] [PubMed]
158. Millan, M.J. Dual-and triple-acting agents for treating core and comorbid symptoms of major depression: Novel concepts, new drugs. Neurotherapeutics 2009, 6, 53–77. [CrossRef] [PubMed]
159. Schmidt, P.J.; Rubinow, D.R. Sex hormones and mood in the perimenopause. Ann. N. Y. Acad. Sci. 2009, 1179, 70–85. [CrossRef] [PubMed]